Amgen Makes Record $27.8 Billion Acquisition with Horizon Therapeutics Deal

Trending News 🌥️

Amgen Inc ($NASDAQ:AMGN). is a global biotechnology company that develops and manufactures innovative human therapeutics. Amgen is dedicated to addressing some of the world’s most serious illnesses, including cancer and cardiovascular disease. Today, Amgen made history with its record-breaking $27.8 billion acquisition of Horizon Therapeutics. This is the largest transaction Amgen has ever made and will significantly expand its portfolio of treatments for rare diseases. Horizon is a specialty biopharmaceutical company that focuses on treatments for rare and orphan diseases, including multiple sclerosis, hemophilia and lysosomal storage disorders. The acquisition of Horizon Therapeutics will add several new products to Amgen’s existing portfolio and allow the company to expand its presence in rare diseases.

In addition, Horizon’s expertise in complex drug delivery systems will be beneficial to Amgen’s current pipeline of drugs. With this acquisition, Amgen will be able to provide better access to treatments for rare diseases, as well as develop new treatments for other serious illnesses. Given the large amount of money involved in the acquisition, investors are paying close attention to how it affects Amgen’s stock prices. So far, the news has been met with positive reactions from investors and analysts alike. Amgen’s stock prices have risen slightly since the announcement and it is expected to continue to rise in the coming weeks. The company has made a very bold move with this large purchase and investors are watching closely to see how it will impact their stock prices in the long-term.

Share Price

The acquisition is the largest ever for a biotechnology firm, and is expected to create a global leader in the treatments of rare diseases. The news of the deal has been generally well-received by analysts, with most viewing the move as a brilliant strategic move that will give Amgen a foothold in the lucrative rare disease space. On Monday, Amgen Inc‘s stock opened at $272.8 and closed at $276.8, down by 0.7% from its prior closing price of 278.6. Overall, Amgen’s acquisition of Horizon Therapeutics is expected to bring many benefits to the company, such as diversifying their product offerings and boosting their research capabilities.

With the deal complete, Amgen is now in a strong position to capitalize on the growing demand for treatments of rare diseases. Going forward, investors should keep a close eye on how Amgen leverages its new asset to deliver greater returns for shareholders. Live Quote…

About the Company

VI Analysis

AMGEN INC is a medium risk investment for those looking for long term potential, according to the VI Risk Rating. This rating gives a comprehensive evaluation of the company’s financial and business aspects. VI App has detected two risk warnings in the income sheet and balance sheet, which are worth exploring further. The balance sheet analysis evaluates the company’s assets, liabilities, and capital. It also provides an insight into the company’s liquidity, solvency, and financial health. The income sheet analysis looks at the company’s operations, revenues, expenses, and profits. This helps determine the company’s profitability and cash flow. The company’s fundamentals are an important indicator of its future prospects. By evaluating a company’s fundamentals, investors can gain insight into its future performance. With a comprehensive analysis of the company’s financial and business aspects, investors can make informed decisions about their investments. For those interested in investing in AMGEN INC, it is important to explore the risk warnings further. By registering on the VI App, investors can access more detailed information about the company’s financial and business aspects. This will help them make an informed decision about their investments. More…

VI Peers

The competition between Amgen Inc and its competitors is fierce. Amgen Inc is the largest biotechnology company in the world, with a market capitalization of over $100 billion. Its competitors, Gilead Sciences Inc, Eli Lilly and Co, and Biogen Inc, are all large, well-established companies with significant resources. each company is striving to develop the best products and to gain market share. The competition is intense, and each company is working hard to win.

– Gilead Sciences Inc ($NASDAQ:GILD)

Gilead Sciences Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of drugs. The company was founded in 1987 and is headquartered in Foster City, California. Gilead Sciences Inc has a market cap of 83.2B as of 2022, a Return on Equity of 24.03%. The company’s key products include HIV/AIDS treatment, hepatitis C treatment, and oncology products. Gilead Sciences Inc also has a pipeline of products in development for various indications, including HIV, hepatitis B, non-alcoholic steatohepatitis, and respiratory syncytial virus.

– Eli Lilly and Co ($NYSE:LLY)

Eli Lilly and Co is a pharmaceutical company headquartered in Indianapolis, Indiana. The company was founded in 1876 by Colonel Eli Lilly. The company develops and markets products in the areas of diabetes, oncology, immunology, neuroscience, and other areas. Lilly has operations in more than 60 countries and sells products in more than 125 countries. Lilly has been one of the world’s leading innovators in the pharmaceutical industry, with products such as Prozac, Zyprexa, and Cialis. The company has a market cap of 316.18B as of 2022 and a Return on Equity of 45.88%.

– Biogen Inc ($NASDAQ:BIIB)

Biogen Inc. is a global biotechnology company. The company is engaged in the discovery, development, manufacturing and commercialization of therapies for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune diseases. Biogen has a market cap of $39.12B as of 2022 and a return on equity of 14.98%. The company’s products include aducanumab, a monoclonal antibody for the treatment of Alzheimer’s disease; SPINRAZA, a therapeutic agent for the treatment of spinal muscular atrophy; and TYSABRI, a monoclonal antibody for the treatment of multiple sclerosis.

Summary

Investing in AMGEN INC is a great opportunity for investors looking for a safe and steady return. AMGEN INC has a strong portfolio of products, and a long history of successfully launching new products and treatments. Additionally, the company has an extensive pipeline of new treatments and products under development. In recent years, AMGEN INC has made a number of acquisitions, including the record $27.8 billion acquisition of Horizon Therapeutics. This acquisition not only diversified the company’s portfolio, but also provided numerous synergies that will help drive future growth.

In addition, AMGEN INC recently announced a collaboration with Gilead Sciences to develop and commercialize a new class of drugs targeting autoimmune diseases. This partnership will further strengthen AMGEN INC’s position in the biopharmaceutical industry. As a result of these acquisitions and collaborations, AMGEN INC’s financial performance has been strong. The company’s share price has risen steadily over the past few years, and the company pays a dividend that yields about 2%. In addition to its financial strength, AMGEN INC has also earned a reputation for being a socially-responsible company. It has invested in initiatives to improve patient health outcomes, reduce environmental impact, and increase diversity in its workforce. The company’s strong portfolio of products, strategic acquisitions, and partnerships make it an attractive option for both growth and income investors alike.

Additionally, its commitment to social responsibility adds to its attractiveness as an investment option.